RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study.
medRxiv : the preprint server for health sciences（2020）
摘要
These results support selection of the BNT162b2 vaccine candidate for Phase 2/3 large-scale safety and efficacy evaluation, currently underway.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要